Journal issues > Issue 6, October 2018 > Emerging M+ RCC treatments from EAU Guidelines

Emerging M+ RCC treatments from EAU Guidelines

By: L. Moris , E. Roussel MD, PhD, T. Van den Broeck

Thanks to our improved understanding of the molecular pathogenesis of metastatic renal cell carcinoma, multiple new treatment agents have appeared and extended our therapeutic possibilities. Novel molecular-targeted agents have vastly replaced cytokine therapies but pointed out new challenges in finding the optimal sequence and/or combination in treating metastatic renal cell carcinoma patients. This review focusses on the emerging therapeutic options according to the European Association of Urology guidelines in the rapidly changing renal cell carcinoma landscape.

(BELG J MED ONCOL 2018;12(6):293–300)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top